目的：研究早产儿呼吸窘迫综合征采取肺表面活性物质联合NCPAP治疗的临床应用价值。方法：选取收治的30例呼吸窘迫综合征的早产儿，随机分为两组，每组15例。对照组采取NCPAP治疗，治疗组加用肺表面活性物质治疗，对比分析两组临床表现及各项观察指标。结果：治疗组早产儿临床反应改善情况、早产儿NCPAP参数变化及病理变化改善情况明显优于对照组（ P＜0.05）；治疗组转为机械通气辅助治疗的早产儿少于对照组（P＜0.05）。结论：肺表面活性物质联合NCPAP治疗早产儿呼吸窘迫综合征疗效显著，是目前治疗早产儿呼吸窘迫综合征的首选方法，值得临床推广应用。%Objective To study the clinical value of pulmonary surfactant combine with NCPAP in treatment of respiratory distress syn-drome in premature children. Method 30 cases of premature children with respiratory distress syndrome were selected,they were randomly di-vided into two groups,15 cases of each group. The control group was treated with NCPAP,the treatment group were treated with pulmonary sur-factant,the clinical manifestations and the observed indicators were compared in two groups. Results The clinical response improvement of preterm children ,NCPAP parameter changes in preterm children and the improve situation of pathological changes in the treatment group was better than that of the control group( P<0. 05);The Preterm children into mechanical ventilation adjuvant therapy in the treatment group was less than that of the control group( P<0. 05). Conclusion Pulmonary surfactant combine with NCPAP in treatment of respiratory distress syn-drome in premature children has a significant effect,is the preferred method for treatment of premature infants with respiratory distress syn-drome,worthy of clinical promotion and application.
展开▼
